Fludarabine Phosphate
FDA-approved product (injectable, injection), marketed as Fludara, Fludarabine Phosphate, Oforta.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Chronic lymphocytic leukemia
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Purine analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fludarabine Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PlecanatideExisting use: Constipation52.2% AI-predicted activityagainst K. pneumoniae15 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
NCT03263208 · start 2017-08-16
Registered record
- Registry ID
- NCT03263208
- Conditions
- B-cell Acute Lymphocytic Leukemia
- Interventions
- Cyclophosphamide; Fludarabine; CD19 CAR-T
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Unknown
- Start
- 2017-08-16
- Completion
- 2019-07
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionB-cell Acute Lymphocytic LeukemiaInterventionCyclophosphamide; Fludarabine; CD19 CAR-TPhasePhase 1 / Phase 2Registry statusUnknownOpen Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
NCT03081780 · start 2017-04-27
Registered record
- Registry ID
- NCT03081780
- Conditions
- Refractory Acute Myelogenous Leukemia; Relapsed Acute Myelogenous Leukemia
- Interventions
- FATE-NK100
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-04-27
- Completion
- 2020-12-01
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRefractory Acute Myelogenous Leukemia; Relapsed Acute Myelogenous LeukemiaInterventionFATE-NK100PhasePhase 1Registry statusCompletedStudy of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
NCT02356159 · start 2015-09-24
Registered record
- Registry ID
- NCT02356159
- Conditions
- Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma
- Interventions
- Rituximab; Conditioning chemotherapy; TMS; FLAG; EPOCH-F; Hematopoietic stem cell transplant; Palifermin; Acetaminophen; Diphenhydramine; Prednisone; Epinephrine; IV Saline; ECG; ECHO; MUGA; DEXA; CT chest; PET; MRI; BM aspirate; BM biopsy; Lumbar puncture
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2015-09-24
- Completion
- 2025-03-25
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia +1 moreInterventionRituximab; Conditioning chemotherapy; TMS; FLAG +18 morePhasePhase 1 / Phase 2Registry statusCompletedPilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas
NCT02409576 · start 2015-02
Registered record
- Registry ID
- NCT02409576
- Conditions
- Ewing Sarcoma; Rhabdomyosarcoma
- Interventions
- Expanded , Activated NK cells
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Unknown
- Start
- 2015-02
- Completion
- 2020-09
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEwing Sarcoma; RhabdomyosarcomaInterventionExpanded , Activated NK cellsPhasePhase 1 / Phase 2Registry statusUnknownCombined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
NCT02199041 · start 2014-07-11
Registered record
- Registry ID
- NCT02199041
- Conditions
- Hematological Malignancies
- Interventions
- Cyclophosphamide; Thiotepa; Fludarabine; Melphalan; Mesna; G-CSF; Mycophenolate mofetil; Tacrolimus; Methylprednisolone; Total lymphoid irradiation; Lymphocyte infusions; CliniMACS
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2014-07-11
- Completion
- 2017-05-23
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHematological MalignanciesInterventionCyclophosphamide; Thiotepa; Fludarabine; Melphalan +8 morePhasePhase 2Registry statusTerminatedA Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
NCT01696461 · start 2013-05
Registered record
- Registry ID
- NCT01696461
- Conditions
- Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia
- Interventions
- Plerixafor
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-05
- Completion
- 2016-08
- Enrolment
- 127
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelated Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome +4 moreInterventionPlerixaforPhasePhase 2Registry statusCompletedMulticenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
NCT01582048 · start 2012-04
Registered record
- Registry ID
- NCT01582048
- Conditions
- Patients Receiving Mismatched Allogeneic HCT
- Interventions
- immunosuppression
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2012-04
- Completion
- 2016-08-17
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPatients Receiving Mismatched Allogeneic HCTInterventionimmunosuppressionPhasePhase 2Registry statusTerminatedReduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
NCT01339910 · start 2011-06
Registered record
- Registry ID
- NCT01339910
- Conditions
- Leukemia, Myelocytic, Acute
- Interventions
- Fludarabine and Busulfan; Fludarabine and Melphalan; Busulfan and Fludarabine; Busulfan and Cyclophosphamide; Cyclophosphamide and Total Body Irradiation
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2011-06
- Completion
- 2017-10-16
- Enrolment
- 272
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia, Myelocytic, AcuteInterventionFludarabine and Busulfan; Fludarabine and Melphalan; Busulfan and Fludarabine; Busulfan and Cyclophosphamide +1 morePhasePhase 3Registry statusTerminatedInternational Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
NCT01117441 · start 2010-06
Registered record
- Registry ID
- NCT01117441
- Conditions
- Leukemia
- Interventions
- PEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; mercaptopurine; methotrexate; prednisone; thioguanine; vincristine sulfate; vindesine; daunoxome; fludarabine; Radiation Therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-06
- Completion
- 2021-12-31
- Enrolment
- 6,136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemiaInterventionPEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride +13 morePhasePhase 3Registry statusCompletedBusulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
NCT01131169 · start 2010-05
Registered record
- Registry ID
- NCT01131169
- Conditions
- Multiple Myeloma
- Interventions
- busulfan, melphalan and fludarabine; busulfan, melphalan and fludarabine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-05
- Completion
- 2020-05-15
- Enrolment
- 66
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple MyelomaInterventionbusulfan, melphalan and fludarabine; busulfan, melphalan and fludarabinePhasePhase 2Registry statusCompletedStudy to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT01088048 · start 2010-03-25
Registered record
- Registry ID
- NCT01088048
- Conditions
- Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
- Interventions
- Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-03-25
- Completion
- 2015-04-28
- Enrolment
- 241
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIndolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell LymphomaInterventionIdelalisib; Rituximab; Bendamustine; Ofatumumab +5 morePhasePhase 1Registry statusCompletedA Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
NCT00772486 · start 2008-09
Registered record
- Registry ID
- NCT00772486
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- ISF35
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2013-04
- Enrolment
- 13
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Lymphocytic LeukemiaInterventionISF35PhasePhase 1Registry statusCompletedChlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma
NCT00608374 · start 2006-06
Registered record
- Registry ID
- NCT00608374
- Conditions
- Lymphoma
- Interventions
- chlorambucil; fludarabine phosphate; quality-of-life assessment
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-06
- Completion
- 2013-01
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionchlorambucil; fludarabine phosphate; quality-of-life assessmentPhasePhase 3Registry statusCompletedMethotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia
NCT00278265 · start 2005-06
Registered record
- Registry ID
- NCT00278265
- Conditions
- T-Cell Large Granular Lymphocytic Leukemia
- Interventions
- MTX followed by fludarabine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2005-06
- Completion
- 2009-12
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionT-Cell Large Granular Lymphocytic LeukemiaInterventionMTX followed by fludarabinePhasePhase 2Registry statusTerminatedAlemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00118352 · start 2005-03
Registered record
- Registry ID
- NCT00118352
- Conditions
- Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; N
- Interventions
- alemtuzumab; total-body irradiation; fludarabine phosphate; cyclosporine; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; graft versus host disease prophylaxis/therapy; laboratory biomarker analysis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2015-05-26
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma +21 moreInterventionalemtuzumab; total-body irradiation; fludarabine phosphate; cyclosporine +5 morePhasePhase 2Registry statusCompleted